associated with excessive plasma cell differentiation and produces truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain. Early-stage IPSID responds to antibiotics (30–70% complete remission). Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma. Patients not responding to antibiotic therapy are considered for treatment with combination chemotherapy used to treat low-grade lymphoma.

MU HEAVY CHAIN DISEASE

The secretion of isolated mu heavy chains into the serum appears to occur in a very rare subset of patients with CLL. The only features that may distinguish patients with mu heavy chain disease are the presence of vacuoles in the malignant lymphocytes and the excretion of kappa light chains in the urine. The diagnosis requires ultracentrifugation or gel filtration to confirm the nonreactivity of the paraprotein with the light chain reagents because some intact macroglobulins fail to interact with these serums. The tumor cells seem to have a defect in the assembly of light and heavy chains because they appear to contain both in their cytoplasm. Such patients are not treated differently from other patients with CLL **(Chap. 107)**.

FURTHER READING

ATTAL M et al: IFM 2009 study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376:1311, 2017.

CORRE J et al: Risk factors in multiple myeloma: is it time for a revision? Blood 137:16, 2021.

HIDESHIMA T, ANDERSON KC: Signaling pathway mediating myeloma cell growth and survival. Cancers (Basel) 13:216, 2021.

HILLENGASS J et al: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302, 2019.

HUNTER ZR et al: Genomics, signaling, and treatment of Waldenström macroglobulinemia. J Clin Oncol 35:994, 2017.